Vaxcyte updates on programs for VAX-31

24 January 2026

US clinical-stage vaccines developer Vaxcyte (Nasdaq: PCVX) on Friday provided updates on the continued advancement of VAX-31, the company’s next-generation 31-valent pneumococcal conjugate vaccine (PCV) candidate, across its adult and infant clinical programs.

For the VAX-31 adult indication, the first participants have been dosed in a Phase III trial evaluating VAX-31 when administered concomitantly with a licensed seasonal influenza vaccine in pneumococcal-naïve adults aged 50 years and older (OPUS-2 trial).

Additionally, Vaxcyte plans to initiate a separate Phase III trial in the first quarter of 2026 evaluating VAX-31 in adults who have previously received a pneumococcal vaccine (OPUS-3 trial). For the VAX-31 infant indication, the Company has completed enrollment in its Phase II dose-finding study evaluating VAX-31 in healthy infants.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK